The safety of an adeno-associated virus (AAV) carrying Retinoid Isomerohydrolase RPE65 (RPE65) cDNA for treating Leber’s congenital amaurosis (LCA) has been investigated and the results showed that the treatment does not pose any major adverse effect [112]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.